Evidence map›Paper›PMID 29471874›Full record

ArticleGenome medicine2018

Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment.

Antoinette MaassenVanDenBrink, Gisela M Terwindt, Arn M J M van den Maagdenberg

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genome medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. The role of erenumab in the treatment of migraine.Therapeutic advances in neurological disorders · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Antoinette MaassenVanDenBrinkDepartment of Internal Medicine, Division of Vascular Medicine and Pharmacology, Erasmus MC, Rotterdam, The Netherlands.
Gisela M TerwindtDepartment of Neurology, Leiden University Medical Centre, Leiden, The Netherlands.
Arn M J M van den MaagdenbergDepartment of Neurology, Leiden University Medical Centre, Leiden, The Netherlands. A.M.J.M.van_den_Maagdenberg@lumc.nl.
Leiden University Medical Center · NLErasmus MC · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Specific prophylactic migraine treatments are urgently needed because of the unmet needs of many migraine patients. Antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor have recently shown efficacy in episodic and chronic migraine and will be available soon.

Indexed as

Antibodies, MonoclonalCalcitonin Gene-Related PeptideHumansMigraine DisordersMolecular Targeted TherapyReceptors, Calcitonin Gene-Related PeptideAntibodies, MonoclonalCALCA protein, humanCalcitonin Gene-Related PeptideReceptors, Calcitonin Gene-Related Peptide

Identifiers

PMID29471874
PMCPMC5824555
OpenAlexW2794018207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.